Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.52 |
| ▸ | RXRG | P48443 | 16/20 | 0.52 |
| ▸ | RARB | P10826 | 7/20 | 0.51 |
| ▸ | RARG | P13631 | 7/20 | 0.51 |
| ▸ | RARA | P10276 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 13/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037041 | 1.00 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037055 | 0.94 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL6037057 | 0.94 | RXRA (0.52) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8308287 | 0.78 | RXRA (0.35) | RXRA | |
| SCHEMBL8309891 | 0.77 | FFAR1 (0.46) | RXRAPPARG | |
| SCHEMBL8309889 | 0.77 | FFAR1 (0.46) | RXRAPPARG | |
| SCHEMBL8309207 | 0.77 | RXRA (0.48) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8309204 | 0.77 | RXRA (0.48) | RXRARXRGRARBRARGRARA | |
| SCHEMBL8311006 | 0.73 | ACHE (0.37) | RXRA | |
| SCHEMBL8311004 | 0.73 | ACHE (0.37) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | claimed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | claimed |
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | disclosed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0800504-B1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARM INC (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RXRA 6/4885RXRG 3/4885RARB 13/4885 |
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | RXRA 6/4885RXRG 3/4885RARB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.